Abstract: TH-PO1086
Prevalence and Factors Associated with Hyperkalemia in Outpatients with CKD
Session Information
- CKD Progression and Complications: Diagnosis, Prognosis, Risk Factors
November 02, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: CKD (Non-Dialysis)
- 2302 CKD (Non-Dialysis): Clinical, Outcomes, and Trials
Authors
- Perez-Navarro, L. Monserrat, Hospital General de Mexico Dr Eduardo Liceaga, Ciudad de Mexico, Ciudad de Mexico, Mexico
- Valdez-Ortiz, Rafael, Hospital General de Mexico Dr Eduardo Liceaga, Ciudad de Mexico, Ciudad de Mexico, Mexico
- Reyna-Blanco, Juan, Hospital General de Mexico Dr Eduardo Liceaga, Ciudad de Mexico, Ciudad de Mexico, Mexico
Background
Hyperkalemia (HK) is a frequent complication of chronic kidney disease (CKD), with a prevalence of between 14-20%, which is associated with different factors, such as the use of some antihypertensives (ARA's, IECAS), age, gender, Diabetes Mellitus (DM), cancer. Our aim was to determine the prevalence and factors associated with HK in patients with CKD.
Methods
Transversal study. Patients with CKD who attended the nephrology service of the Hospital General de México during the period Feb 2019 to August 2022 were included. The prevalence and factors associated with HK (K>5) by CKD stage were estimated using regression logistics (95% CI).
Results
1368 patients were included, with an average age of 55.2±18.8 years; 51% of the population female. The time of suffering from CKD was 1 year (RIQ 2); 16% (223) are in renal replace therapy (93% HD). 74% were overweight or obese, with a mean BMI of 27.1±5.4. The main comorbidities were anemia (55%), hyperuricemia (52%), hypertriglyceridemia (50%), DM (46%), Hypertension (26%). The prevalence of HK was 25% (347), Figure 1.
The factors associated with HK by CKD stage were stage 3a, DM (OR 7.5, 1.6-34.7), the use of IECAS (OR 3.7, 12-11.2) and hypertension (OR3.5, 1.1-10.9); in stage 3b, DM (OR 2.06, 1.1-3.8), AINES (OR 2.5, 1.04-6.2, 0.04), Glucose >100 ml/DL (OR 2.01, 1.04-3.8); stage 4 used ARAS (OR 3.9, 1.3-11.3); and in Stage 5 was identified the male gender (OR 1.6, 1.13-2.45) and being on HD (OR 1.8, 1.2-2.7).
Conclusion
HK presented a high prevalence in our population, which increases the risk of death, cardiovascular disease, and hospitalization. An intentional search is necessary from the early stages of CKD, as well as the different associated factors according to the CKD stage.